Abstracts Archive - Page 1371 of 2607 - ACR Meeting Abstracts

Abstract Number: 2772 • 2018 ACR/ARHP Annual Meeting
Incidence of Cardiovascular Events in Giant Cell Arteritis: A Matched-Control Study
Florencia Beatriz Mollerach¹, Marina Scolnik², Nicolas Martin Marin Zucaro³, Jose Maximiliano Martinez P⁴ and Enrique R Soriano², ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²Rheumatology Unit, Internal Medicine Service. Hospital Italiano Buenos Aires. Argentina, Buenos Aires, Argentina, ³Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Capital Federal, Argentina, ⁴Rheumatology, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: Cardiovascular risk in systemic vasculitis may be higher than in normal population, but there is scarce data. Ethnic component plays a role on certain…
Abstract Number: 2773 • 2018 ACR/ARHP Annual Meeting
Diagnostic and Therapeutic Management of a Suspected Case of GCA: An Opinion Survey
Henri Guillet¹, Raphaël Porcher², Alain Saraux³, Loïc Guillevin⁴, Luc Mouthon⁴ and Alexis Régent⁴, ¹Département d'aval des urgences, CHU Henri Mondor, Créteil, France, ²Université Paris Descartes Sorbonne Paris, Paris, France, ³Rheumatology, CHU Brest, Brest, France, ⁴Institut Cochin, INSERM U1016, CNRS UMR 8104, PARIS, France
Background/Purpose: Giant-cell arteritis (GCA) is the most common vasculitis. Specialists have formulated recommendations on how to manage a patient with a possible diagnosis of GCA.…
Abstract Number: 2774 • 2018 ACR/ARHP Annual Meeting
Treatment with Methotrexate and Risk of Ischemic Relapses in Patients with Giant Cell Arteritis in Clinical Practice
Judit Font Urgelles¹, Luis Rodriguez-Rodriguez², Zulema Rosales Rosado^1,2, Dalifer Freites Núñez², Leticia Leon², Inmaculada Morado¹, Esperanza Pato Cour¹, Juan A Jover Jover¹, Benjamín Fernández-Gutiérrez¹ and Lydia A Alcazar², ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain
Background/Purpose: Clinical trials have shown the efficacy of Methotrexate (MTX) in giant cell arteritis (GCA) but it is necessary to corroborate these results in real…
Abstract Number: 2775 • 2018 ACR/ARHP Annual Meeting
Neutrophil to Lymphocyte Ratio Predicts Glucocorticoid Resistance in Polymyalgia Rheumatica
Claire Owen^1,2, Christopher McMaster², David Liew^1,2, Jessica Leung^1,2, Andrew Scott^3,4,5 and Russell Buchanan^2,6, ¹Medicine, University of Melbourne, Parkville VIC, Australia, ²Rheumatology, Austin Health, Heidelberg VIC, Australia, ³Medicine, University of Melbourne, Heidelberg VIC, Australia, ⁴Molecular Imaging and Therapy, Austin Health, Heidelberg VIC, Australia, ⁵Olivia Newton-John Cancer Research Institute, and School of Cancer Medicine, La Trobe University, Heidelberg VIC, Australia, ⁶Medicine, University of Melbourne, Parkville, Australia
Background/Purpose: Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) have been demonstrated to correlate with disease activity and predict treatment response in…
Abstract Number: 2776 • 2018 ACR/ARHP Annual Meeting
Interleukin-6 Expression in Inflamed and Non-Inflamed Temporal Arteries from Patients with Giant Cell Arteritis
Nicolò Pipitone¹, Francesco Muratore², Ione Tamagnini³, Alberto Cavazza⁴, Luca Cimino⁵, Luigi Boiardi², Giovanna Restuccia⁶, Martina Bonacini⁷, Stefania Croci⁷ and Carlo Salvarani⁸, ¹Rheumatology Unit, Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Italy, ²Unit of Rheumatology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, Reggio Emilia, Italy, ³Pathology Unit, Department of Oncology, Arsicpedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, ⁴Pathology Unit, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ⁵Ophthalmology Unit, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ⁶Rheumatology Unitn, Arcispedale S Maria Nuova, IRCCS, 42100, Italy, ⁷Unit of Clinical Immunology, Allergy and Advanced Biotechnologies, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, Reggio Emilia, Italy, ⁸Azienda USL-IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: To evaluate if interleukin-6 (IL-6) expression in the temporal artery biopsy (TAB) specimens may differentiate patients with giant cell arteritis (GCA) from those without.…
Abstract Number: 2777 • 2018 ACR/ARHP Annual Meeting
Dynamics in Peripheral Blood Cell Counts in Giant Cell Arteritis before Treatment, during Treatment and in Treatment-Free Remission
Jacoba C. Graver¹, Yannick van Sleen², Wayel H. Abdulahad², Annemieke M.H. Boots², Maria Sandovici² and Elisabeth Brouwer³, ¹Rheumatoloy and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³University of Groningen University Medical Center, Groningen, Netherlands
Background/Purpose: Giant cell arteritis (GCA) is an inflammatory disease of large vessels requiring long-term treatment with glucocorticoids. The immunopathology is characterized by vessel infiltrating innate…
Abstract Number: 2778 • 2018 ACR/ARHP Annual Meeting
High Prevalence of Vascular Surgery and Autoimmune Comorbidity in Takayasu Arteritis
Tsuyoshi Shirai¹, Tomoyuki Muto², Yuko Shirota¹, Hiroshi Fujii¹, Tomonori Ishii³ and Hideo Harigae¹, ¹Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, ²Tohoku University Graduate School of Medicine, Sendai, Japan, ³Clinical Research, Innovation and Education Center, Tohoku University Hospital, Sendai, Japan
Background/Purpose: Large vessel vasculitis (LVV) is the arteritis in aorta and its major branches, and classified into Takayasu arteritis (TAK) and giant cell arteritis (GCA).…
Abstract Number: 2779 • 2018 ACR/ARHP Annual Meeting
Long-Term Outcome and Prognostic Factors after Aortic Valve Surgery Due to Aortic Valve Regurgitation in Patients with Takayasu Arteritis
So Hye Nam¹, Dae-Hee Kim², Doo-Ho Lim³, Ji Seon Oh¹, Seokchan Hong¹, Yong-Gil Kim¹, Chang Keun Lee¹ and Bin Yoo¹, ¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South), ²Division of Cardiology, Department of Internal medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South), ³Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea, Republic of (South)
Background/Purpose: Aortic valve (AV) surgery is often performed for aortic regurgitation (AR) in patients with Takayasu arteritis (TA). However, data on the long-term outcomes, including…
Abstract Number: 2780 • 2018 ACR/ARHP Annual Meeting
Insufficient Use of Corticosteroids Results in Higher Relapse in Takayasu Arteritis
Tomoyuki Muto¹, Tsuyoshi Shirai², Hiroshi Fujii¹, Tomonori Ishii³ and Hideo Harigae³, ¹Tohoku University Graduate School of Medicine, Sendai, Japan, ²Medicine, Stanford University School of Medicine, Stanford, CA, ³Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan
Background/Purpose: Takayasu arteritis (TAK) is the chronic granulomatous inflammation of the aorta, its major branches. Although Corticosteroids, such as prednisolone (PSL), and immunosuppressants are key…
Abstract Number: 2781 • 2018 ACR/ARHP Annual Meeting
Long Term Follow-up Results of Takayasu Arteritis Cohort: A Tertiary-Single Center Study
Sema Kaymaz Tahra¹, Fatma Alibaz-Oner¹ and Haner Direskeneli², ¹Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, ²Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: To assess the clinical characteristics and long term follow-up outcomes of patients with Takayasu’s arteritis (TAK) in a tertiary referral center. Methods: In this…
Abstract Number: 2782 • 2018 ACR/ARHP Annual Meeting
Is It Necessary to Hold Anticoagulation Prior to Temporal Artery Biopsy?
Mahjabeen Haq¹, Danielle Schwartz¹, Monica Weinberg¹, Jillian Cepeda¹, Erin Taub², Asha Patniak³ and Qingping Yao⁴, ¹Department of Medicine-Rheumatology, Allergy, and Immunology Division, Stony Brook University Hospital, stony brook, NY, ²Department of Medicine, Stony Brook University Hospital, stony brook, NY, ³Stony Brook University Hospital, Stony Brook, NY, ⁴Rheumatology, Allergy and Immunology, Stony Brook University Hospital, Stony Brook, NY
Background/Purpose: Giant cell arteritis (GCA) and Temporal arteritis (TA) is characterized by chronic granulomatous inflammation in medium and large-sized vessels. It affects 20 in 100,000…
Abstract Number: 2783 • 2018 ACR/ARHP Annual Meeting
EULAR Task Force Recommendations for a Minimum Core Set of Parameters to be Collected in Giant Cell Arteritis Registries and Databases
Lisa Ehlers¹, Johan Askling², Johannes W. J. Bijlsma³, Maria C. Cid⁴, Maurizio Cutolo⁵, Bhaskar Dasgupta⁶, Christian Dejaco^7,8, William G Dixon⁹, Nils Feltelius^10,11, Axel Finckh¹², Kate Gilbert¹³, Sarah Mackie¹⁴, Alfred Mahr¹⁵, Eric L. Matteson¹⁶, Lorna Neill¹⁷, Carlo Salvarani^18,19, Wolfgang A. Schmidt²⁰, Anja Strangfeld²¹, Ronald van Vollenhoven²² and Frank Buttgereit¹, ¹Department of Rheumatology and Clinical Immunology, Charité University Hospital Berlin, Berlin, Germany, ²Unit of Clinical Epidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ³Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴University of Barcelona, Barcelona, Spain, ⁵Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ⁶Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, ⁷Department of Rheumatology and Immunology, Medical University Graz, Graz, Austria, Graz, Austria, ⁸Rheumatology, Hospital of Bruneck, Bruneck, Italy, ⁹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ¹⁰Medical Products Agency, Uppsala, Sweden, ¹¹Cross-Committee Task Force on Registries at the European Medicines Agency, London, United Kingdom, ¹²University Hospital of Geneva, Geneva, Switzerland, ¹³Patient Representative from PMRGCAuk, London, United Kingdom, ¹⁴NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, University of Leeds, Leeds, United Kingdom, ¹⁵Internal Medicine, Saint-Louis Hospital, Paris Diderot University, Paris, France, ¹⁶Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ¹⁷Patient Representative from PMR-GCA Scotland, Perth, United Kingdom, ¹⁸Università di Modena e Reggio Emilia, Modena, Italy, ¹⁹Azienda USL-IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Italy, ²⁰Medical Center for Rheumatology and Clinical Immunology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, ²¹Epidemiology, German Rheumatism Research Center, Berlin, Germany, ²²Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands
Background/Purpose: Giant cell arteritis (GCA) represents the most common form of primary systemic vasculitis, and is frequently associated with comorbidities related either to the disease…
Abstract Number: 2784 • 2018 ACR/ARHP Annual Meeting
Multi Modal Imaging Algorithm to Improve the Accuracy for the Diagnosis of Giant Cell Arteritis
Augustin Lecler¹, Thomas Sené², Herve Picard³, Tifenn Leturcq², Kevin Zuber³, Frederique Charbonneau¹, Catherine Vignal-Clermont⁴ and Gaelle Clavel², ¹Department of Radiology, Fondation Ophtalmologique A. de Rothschild, Paris, France, ²Internal Medecine, Fondation Ophtalmologique A. de Rothschild, Paris, France, ³Clinical Research Unit, Fondation Ophtalmologique A. de Rothschild, Paris, France, ⁴Ophtalmology, Fondation Ophtalmologique A. de Rothschild, Paris, France
Background/Purpose: Giant Cell Arteritis (GCA) is the most common systemic vasculitis in patient over 50 years of age. It is a medical emergency as it…
Abstract Number: 2785 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Ustekinumab, an Interleukin-12/23 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: 1-Year Results of a Phase 2, Randomized Placebo-Controlled, Crossover Study
Ronald van Vollenhoven¹, Bevra H Hahn², George C Tsokos³, Carrie Wagner⁴, Peter Lipsky⁵, Benjamin Hsu⁴, Marc Chevrier⁴, Robert Gordon⁴, Kim Hung Lo⁴, Manon Triebel⁶, Kaiyin Fei⁴ and Shawn Rose⁴, ¹Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ²University of California, Los Angeles, CA, ³Beth Israel Hospital, Boston, MA, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵AMPEL BioSolutions and RILITE Research Institute, Charlottesville, VA, ⁶Janssen Biologics Europe, Leiden, Netherlands
Background/Purpose: Both the IL-12 and IL-23 pathways have been linked to SLE pathogenesis. The anti-IL-12/23 p40 monoclonal antibody ustekinumab (UST), which is approved for psoriasis,…
Abstract Number: 2786 • 2018 ACR/ARHP Annual Meeting
Prospective Multicenter Validation Study of the Lupus Low Disease Activity State – a Treatment Target for Systemic Lupus Erythematosus
Vera Golder¹, Rangi Kandane-Rathnayake², Molla Huq³, Worawit Louthrenoo⁴, Shue-Fen Luo⁵, Yeong-Jian Wu⁶, Aisha Lateef⁷, Sargunan Sockalingam⁸, Susan Morton⁹, Sandra V. Navarra¹⁰, Leonid Zamora¹¹, Laniyati Hamijoyo¹², Yasuhiro Katsumata¹³, Masayoshi Harigai¹⁴, Madelynn Chan¹⁵, Sean O'Neill¹⁶, Fiona Goldblatt¹⁷, Chak Sing Lau¹⁸, Zhan-Guo Li¹⁹, Alberta Y. Hoi², Mandana Nikpour²⁰ and Eric Morand²¹, ¹School of Clinical Sciences at Monash Health, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ²School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ³The University of Melbourne at St Vincent's Hospital, Melbourne, Australia, ⁴Division of Rheumatology, Department of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand, ⁵Division of Rheumatology, Allergy and Immunology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁶Chang Gung University, Taoyuan County, Taiwan, ⁷Medicine, Division of Rheumatology, National University Hospital of Singapore, Singapore, Singapore, ⁸University of Malaya, Kuala Lumpur, Malaysia, ⁹Monash Health, Melbourne, Australia, ¹⁰University of Santo Tomas Hospital, Manila, Philippines, ¹¹Rheumatology, University of Santo Tomas Hospital, Manila, Philippines, ¹²University of Padjadjaran, Bandung, Indonesia, ¹³Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ¹⁴Tokyo Women's Medical University, Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo, Japan, ¹⁵Tan Tock Seng Hospital, Singapore, Singapore, ¹⁶University of New South Wales, Sydney, Australia, ¹⁷Rheumatology, Royal Adelaide Hospital, Adelaide, Australia, ¹⁸Medicine, The University of Hong Kong, Hong Kong, Hong Kong, ¹⁹Department of Rheumatology and Immunology, People’s Hospital, Peking University Health Science Center,, Beijing, China, ²⁰The University of Melbourne, Melbourne, Australia, Melbourne, Australia, ²¹Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia
Background/Purpose: The adoption of treat to target approaches for Systemic Lupus Erythematosus (SLE) requires the definition of a target state validated for improved patient outcomes.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].